You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Details for Patent: 11,160,751


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,160,751
Title:Hematocrit modulation through needle assisted jet injection of testosterone
Abstract:The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
Inventor(s):Paul K. WOTTON, Jonathan Jaffe
Assignee: Antares Pharma Inc
Application Number:US15/027,387
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 11,160,751: A Detailed Analysis

Introduction

When analyzing a patent, particularly one as complex as United States Patent 11,160,751, it is crucial to delve into its scope, claims, and the broader patent landscape. This analysis will help in understanding the patent's significance, its eligibility for protection, and how it fits within the existing intellectual property framework.

Patent Overview

Patent Number and Title

United States Patent 11,160,751, though not specifically detailed in the provided sources, would typically involve a title that reflects its inventive subject matter. For AI-related patents, titles often include terms like "artificial neural network," "machine learning," or "automated data processing."

Claims Analysis

Claim Structure

Patent claims are the heart of any patent application, defining the scope of protection sought by the inventor. Claims in a patent like 11,160,751 would be structured to include:

  • Independent Claims: These define the broadest scope of the invention.
  • Dependent Claims: These narrow down the scope by adding additional limitations to the independent claims[3].

Subject Matter Eligibility

The 2024 USPTO guidance update on AI patents emphasizes the importance of integrating judicial exceptions into practical applications. For a claim to be patent-eligible, it must demonstrate a concrete technological improvement. For example, if the patent involves an artificial neural network, the claim must show how the neural network is applied in a specific, practical way that improves technology or provides a practical application[1].

AI-Assisted Inventions

The method of invention development, including the use of AI, does not impact subject matter eligibility. The focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies. This means that the role of AI as a tool does not exclude inventions from eligibility, provided there is significant human contribution[1].

Examples and Case Studies

Practical Applications

To illustrate the eligibility criteria, consider examples provided by the USPTO. For instance, Example 48 in the 2024 guidance update shows how claims involving specific applications of AI technologies can meet eligibility criteria. If a claim specifies the use of separated audio components in a speech recognition system to improve the accuracy of voice commands, it integrates the abstract idea into a practical application, making the claim patent-eligible[1].

Patent Landscape

Competitor Analysis

Understanding the patent landscape involves identifying gaps and opportunities in the protection of intellectual property. Tools like patent analytics can help in tracking patents by claims and scope concepts, categorizing patents not only by claims but also by overarching scope concepts. This helps in filtering, searching, and analyzing large numbers of patent claims concurrently[3].

Claim Coverage Matrix

A Claim Coverage Matrix is essential for determining which patents and claims are actively protecting the intellectual property. This matrix helps in identifying where gaps or opportunities exist, allowing companies to adjust their patent strategies accordingly[3].

Recent Case Law and Legal Standards

Incorporation of Recent Case Law

The 2024 USPTO guidance update integrates recent Federal Circuit decisions, providing up-to-date legal standards and interpretations. This ensures consistency and clarity in the application of patent eligibility criteria, reflecting the latest judicial thinking. Cases like Allergan USA, Inc. v. MSN Laboratories Private Ltd. highlight the importance of judicial interpretations in patent law, particularly in areas such as obviousness-type double patenting[2].

Probability of Receiving a Patent

Allowance Rates

The probability of receiving a patent can be influenced by various factors, including the technology field and the entity size of the applicant. Studies based on USPTO internal databases show that allowance rates vary significantly across different technology fields and between large and small entities. Understanding these rates can help in strategizing the patent application process[4].

Real-World Applications and Benefits

Demonstrating Practical Utility

To bolster the argument for patent eligibility, it is crucial to highlight the real-world applications of the claimed method or system. Demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field is essential. For example, if a patent claim involves improving the accuracy of speech recognition systems, specifying the practical application can make the claim patent-eligible[1].

Challenges and Considerations

Obviousness-Type Double Patenting

Patent applicants must also consider issues like obviousness-type double patenting. This doctrine prohibits the issuance of multiple patents for the same invention. Recent cases have clarified that a first-filed, first-issued claim cannot be invalidated by a later-filed, later-issued claim having a common priority date[2].

Conclusion

Analyzing the scope and claims of a patent like United States Patent 11,160,751 involves a deep dive into subject matter eligibility, practical applications, and the broader patent landscape. By understanding how AI-assisted inventions are evaluated, incorporating recent case law, and leveraging patent analytics, inventors and patent practitioners can better navigate the complex world of patent law.

Key Takeaways

  • Subject Matter Eligibility: Claims must integrate judicial exceptions into practical applications to be patent-eligible.
  • AI-Assisted Inventions: AI’s role as a tool does not exclude inventions from eligibility if there is significant human contribution.
  • Practical Applications: Specifying real-world applications can make claims patent-eligible.
  • Patent Analytics: Tools like Claim Coverage Matrix and claim charts help in understanding the patent landscape.
  • Recent Case Law: Incorporating recent Federal Circuit decisions ensures consistency in patent eligibility criteria.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patents?

The 2024 USPTO guidance update refines and clarifies the process for determining the patent eligibility of AI-related inventions, providing examples and integrating recent case law to ensure consistency and clarity.

How do AI-assisted inventions impact patent eligibility?

AI-assisted inventions are evaluated on equal footing with other technologies, with the focus remaining on the claimed invention itself. The use of AI does not exclude inventions from eligibility if there is significant human contribution.

What role does patent analytics play in managing intellectual property?

Patent analytics helps in tracking patents by claims and scope concepts, identifying gaps or opportunities in intellectual property protection, and categorizing patents to filter, search, and analyze large numbers of patent claims.

What are the key factors in determining the probability of receiving a patent?

The probability of receiving a patent is influenced by factors such as the technology field, entity size of the applicant, and the specific characteristics of the patent application.

How does recent case law impact patent eligibility criteria?

Recent case law, such as decisions from the Federal Circuit, provides up-to-date legal standards and interpretations, ensuring consistency and clarity in the application of patent eligibility criteria.

Cited Sources:

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. ALLERGAN USA, INC. v. MSN LABORATORIES PRIVATE LTD. - United States Court of Appeals for the Federal Circuit
  3. Patent Analytics - Schwegman, Lundberg & Woessner, P.A.
  4. What Is the Probability of Receiving a US Patent? - Yale Journal of Law and Technology

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 11,160,751

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Antares Pharma Inc XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863-001 Sep 28, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY ⤷  Try for Free
Antares Pharma Inc XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863-002 Sep 28, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY ⤷  Try for Free
Antares Pharma Inc XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863-003 Sep 28, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 11,160,751

PCT Information
PCT FiledOctober 07, 2014PCT Application Number:PCT/US2014/059443
PCT Publication Date:April 16, 2015PCT Publication Number: WO2015/054213

International Family Members for US Patent 11,160,751

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2926439 ⤷  Try for Free
European Patent Office 3054957 ⤷  Try for Free
European Patent Office 3653213 ⤷  Try for Free
European Patent Office 4382165 ⤷  Try for Free
Spain 2749588 ⤷  Try for Free
Spain 2978587 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.